Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

@inproceedings{Kwo2016SimeprevirPS,
  title={Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study},
  author={P. W. Kwo and N. Gitlin and Ronald G Nahass and David A. Bernstein and Kyle P Etzkorn and Sergio Rojter and Eugene R Schiff and Mitchell Davis and Peter J Ruane and Ziad Younes and Ronald Kalmeijer and Rekha Sinha and Monika Peeters and Oliver Lenz and B. Fevery and Guy De La Rosa and Jane Anne Scott and James Witek},
  booktitle={Hepatology},
  year={2016}
}
UNLABELLED Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients. The phase 2 COSMOS study reported high SVR rates in treatment-naive and prior null-responder HCV genotype (GT) 1-infected patients receiving simeprevir+sofosbuvir±ribavirin for 12 or 24 weeks. OPTIMIST-1 (NCT02114177) was a multicenter, randomized, open-label study assessing the efficacy and safety of 12 and 8 weeks of simeprevir+sofosbuvir in HCV… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

Similar Papers

Loading similar papers…